To the Editor Treatment with topical fluorouracil, 5%, compared with placebo reduced risk of surgically treated squamous cell carcinoma (SCC) and Mohs surgery for keratinocyte carcinoma (KC) for 1 year, according to a randomized clinical trial (RCT) report.1 However, because neither of these outcomes was prespecified, these findings should be interpreted very cautiously and should not sway clinical practice.
Katz KA. Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma. JAMA Dermatol. 2018;154(7):850–851. doi:10.1001/jamadermatol.2018.1229
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: